MSB 1.70% $1.16 mesoblast limited

Cell Therapy News/Articles, page-17674

  1. 525 Posts.
    lightbulb Created with Sketch. 139
    Thanks for sharing@Wilba32

    I think it important to also reference Dr Lightner's response to Dr Cheng's letter to the editor re the important role of anti-TNF in treating refractory pCD, suggesting a contributing role of MSCs....

    From Dr Lightner's reply
    "however, by definition, the patients enrolled were refractory to anti-TNF, and their fistulas had not healed despite being on medical therapy. In fact, all patients enrolled had either failed medical therapy or were on stable medical therapy for at least 3 months before study enrollment to minimize any
    confounding with MSC healing."

    Good signs but more work to do

    DYOR

    V




    Reference:
    https://hotcopper.com.au/data/attachments/6130/6130813-fffc85b353415c0e2be642c8ba462686.jpg

 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
$1.16
Change
-0.020(1.70%)
Mkt cap ! $1.318B
Open High Low Value Volume
$1.20 $1.21 $1.14 $9.786M 8.412M

Buyers (Bids)

No. Vol. Price($)
4 78042 $1.15
 

Sellers (Offers)

Price($) Vol. No.
$1.16 189626 1
View Market Depth
Last trade - 16.10pm 27/05/2024 (20 minute delay) ?
Last
$1.16
  Change
-0.020 ( 1.47 %)
Open High Low Volume
$1.21 $1.21 $1.14 1281085
Last updated 15.59pm 27/05/2024 ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.